Biomedical research can hinge on a deceptively small detail: whether a statistical result is reported clearly enough for another scientist to understand, test and potentially reproduce it. A brief article in Immunity, Inflammation and Disease is putting that issue at the center of research on immune disorders, inflammation and related diseases, offering authors a practical set of recommendations for making statistical analyses more transparent. The guidance does not present a new drug, biomarker or experimental discovery. Instead, it targets a less visible part of the scientific process—the methods used to turn biological observations into evidence. Its central message is that strong immunology depends not only on collecting meaningful data, but also on explaining precisely how those data were analyzed, who performed the analysis and whether the underlying information can be independently examined.
The recommendations begin with the SAMPL guidelines, a framework developed for reporting statistical analyses in biomedical publications. SAMPL stands for “Statistical Analyses and Methods in the Published Literature,” and its purpose is to ensure that statistical methods are described accurately, completely and in language that readers can follow. In immune research, this can be especially important because studies often combine multiple types of evidence: cell counts, cytokine concentrations, antibody levels, gene-expression measurements, clinical scores and longitudinal observations. Each type of data may have different distributions, sources of variation and assumptions. A paper that simply states that a “significant difference” was detected leaves unanswered questions about the test used, the comparison made, the size of the effect and the uncertainty surrounding the estimate. SAMPL-style reporting is intended to make those decisions visible rather than burying them behind a final P value.
That transparency matters because statistical significance is not the same as biological or clinical importance. A very small change can produce a low P value in a large study, while a potentially meaningful effect may fail to reach conventional significance in a small one. The statistical analysis should therefore be tied to the research question and study design from the outset. Researchers need to identify what constitutes the primary outcome, distinguish planned analyses from exploratory ones and explain how missing observations, repeated measurements or multiple comparisons were handled. When many outcomes are tested, the probability of obtaining at least one apparently positive result can rise simply by chance unless the analysis accounts for multiplicity. Similarly, when the same participant or experimental subject is measured repeatedly, observations may not be independent, and ordinary tests can underestimate uncertainty if that structure is ignored.
The article also directs authors toward a 2025 review in Allergy that uses practical examples from allergy and clinical immunology. That review emphasizes matching statistical tests to the characteristics of the data rather than selecting familiar methods automatically. For example, continuous measurements may require different approaches depending on whether their distributions are approximately symmetric, heavily skewed or influenced by extreme values. Categorical outcomes, time-to-event data and repeated measurements each call for methods designed around their specific structure. Regression models can help evaluate associations while adjusting for potential confounding variables, but only if their assumptions are assessed. These assumptions may include linearity, independence, constant variance or proportional hazards, depending on the model. If assumptions fail, investigators may need transformations, robust methods, alternative models or a clear explanation of the limitation.
A particularly important recommendation is that authors should identify, in the cover letter, which co-authors were responsible for the statistical analysis. The disclosure is intended to clarify accountability within a research team and give editors and reviewers a better basis for evaluating methodological credibility. Biomedical papers frequently involve collaborations among laboratory scientists, clinicians, epidemiologists and statisticians, and responsibility for data processing and modeling may be distributed across several people. Stating who designed the analysis, handled the data, ran the models and interpreted the results can make that process easier to scrutinize. If a qualified biostatistician contributed to the work, the article recommends acknowledging that role explicitly. Such information does not guarantee that an analysis is correct, but it can expose the chain of responsibility behind the reported conclusions and help reviewers identify whether the expertise required by the study is represented among the authors.
The guidance further urges researchers to make the data underlying their analyses publicly accessible whenever possible. Open datasets allow independent researchers to verify calculations, reproduce figures and test whether conclusions remain stable under alternative analytical choices. They can also reveal how variables were defined, whether exclusions affected the sample and how much uncertainty is present in the findings. In immunology, however, data sharing can involve legitimate challenges. Clinical datasets may contain identifiable information, while genetic, immune-profile or rare-disease data can carry a risk of re-identification even after obvious identifiers are removed. Public access therefore has to be balanced with privacy protections, ethical approvals and appropriate governance. Where unrestricted release is impossible, controlled-access repositories or detailed data-sharing procedures may still improve reproducibility. The recommendation is framed as “whenever possible,” recognizing that transparency must operate within ethical and legal boundaries.
The article’s argument arrives amid growing concern that biomedical papers can be difficult to evaluate when statistical methods are reported incompletely. A reader may be told that a study used a t test, analysis of variance or a nonparametric test, but still lack essential information about prespecified hypotheses, covariate selection, outlier treatment, confidence intervals or corrections for multiple testing. These omissions can make it difficult to distinguish a robust signal from a result shaped by analytical flexibility. Confidence intervals are particularly valuable because they show the range of effect sizes compatible with the data, rather than reducing the result to a binary significant-versus-not-significant label. Reporting effect sizes alongside uncertainty can help readers judge whether an immune response is large enough to matter biologically, clinically or therapeutically.
Rather than treating statistical reporting as an editorial formality at the end of a project, the recommendations encourage researchers to consider it during study planning. The design determines what conclusions can eventually be supported: sample size affects precision and statistical power, randomization reduces systematic differences between groups, and appropriate controls help separate treatment effects from background variation. A statistical analysis plan can specify primary outcomes, models and decision rules before researchers examine the results, reducing the risk that the analysis will be adapted to whichever patterns appear most favorable. Clear reporting can also accelerate peer review by allowing reviewers to focus on scientific interpretation instead of reconstructing the methods from incomplete descriptions. The article concludes that rigorous statistics are not separate from immunology’s biological questions. They are the framework that determines how confidently observations about inflammation, immunity and disease can be converted into reliable knowledge.
Subject of Research: Statistical reporting and analysis practices in immunology, inflammation and disease research
Subject of Research: Medicine
Article Title: Statistical Recommendations for Immunity, Inflammation and Disease
Article References: Ordak, M. (2026). Statistical Recommendations for Immunity, Inflammation and Disease. Immunity, Inflammation and Disease, 14(6), Article e70466. https://doi.org/10.1002/iid3.70466
Image Credits: AI Generated
DOI: 10.1002/iid3.70466
Keywords: immunology, inflammation, statistical reporting, SAMPL guidelines, biomedical research, reproducibility, biostatistics, clinical research
Cite this news
APA
MLA
Chicago
SCIENMAG. (August 28, 2026). Statistical Analysis Offers New Insights Into Immunity, Inflammation, and Disease. https://scienmag.com/statistical-analysis-offers-new-insights-into-immunity-inflammation-and-disease/
SCIENMAG. “Statistical Analysis Offers New Insights Into Immunity, Inflammation, and Disease.” Scienmag, 28 August 2026, https://scienmag.com/statistical-analysis-offers-new-insights-into-immunity-inflammation-and-disease/. Accessed 28 August 2026.
SCIENMAG. “Statistical Analysis Offers New Insights Into Immunity, Inflammation, and Disease.” Scienmag. August 28, 2026. https://scienmag.com/statistical-analysis-offers-new-insights-into-immunity-inflammation-and-disease/
Copy citation
Download RIS
Tags: among othersand clinical outcome measuresbiological data analysis methodsbiomarker dataBiomedical researchevidence-based immunologyimmune disorder researchimmune system data interpretationinflammation and disease studiesmaking transparent statistical reporting crucial for validation and reproducibilityreporting standards in biomedical publicationsreproducibility in immunologySAMPL guidelines for statistical reportingscientific transparency in biomedical studiesstatistical analysis transparencystatistical methods in inflammation research
